Targeting T-Cells
TNeuroPharma was created to provide science-based solutions in the continuing quest to find a treatment for one of today’s most critical public health crises: Alzheimer’s disease. Led by a team of some of the country’s top researchers in Alzheimer’s and other neurodegenerative diseases, TNeuroPharma has developed a new biomarker technology to detect the first signs of Alzheimer’s - focusing on an area poised to be the important breakthrough scientists have been waiting for: t-cells.
What Do Dysfunctional T-cells Do in the Body?
T-cells in brain cause: Aβ, Tau accumulation, Neuroinflammation, Neurodegeneration, Cognitive decline
Our Goal
Our goal is to provide pharmaceutical companies with that “missing piece” : the critical technology to evaluate biomarkers in blood from normal all the way through the AD continuum, through a biomarker kit for pharmaceutical companies performing AD clinical trials. This innovative, less-invasive and more cost-effective technology allows for broader screening for the early detection of Alzheimer’s Disease -- vital in the development of drug treatments to specifically target, and effectively treat, confirmed AD patients
Why We're Different
TNeuroPharma’s technology is a unique advance that is critically needed in the Alzheimer’s disease drug development pipeline. By targeting dysfunctional t-cells, one of the earliest known events in AD progression, drug companies can identify AD patients early in order to develop effective therapies, for the first time allowing companies to study confirmed AD patients all the way through the AD continuum.
Amarantus vs. TNeuroPharma Blood Biomarker
Amarantus- LymPro Assay
Statistically Significant, but 100% overlap between control and AD groups. Therefore biomarker works at a population level, but cannot be used to determine If an individual has the disease
T-Neuro Biomarker Assay
No Overlap Between Groups